Barclays’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-487,230
| Closed | -$23.1M | – | 5211 |
|
|
2025
Q3 | $23.1M | Sell |
487,230
-46,186
| -9% | -$2.24M | 0.01% | 1148 |
|
|
2025
Q2 | $28.5M | Buy |
533,416
+410,253
| +333% | +$18.6M | 0.01% | 946 |
|
|
2025
Q1 | $4.99M | Sell |
123,163
-9,674
| -7% | -$410K | ﹤0.01% | 1917 |
|
|
2024
Q4 | $3.7M | Buy |
132,837
+5,169
| +4% | +$157K | ﹤0.01% | 2422 |
|
|
2024
Q3 | $3.66M | Buy |
127,668
+71,652
| +128% | +$1.87M | ﹤0.01% | 2347 |
|
|
2024
Q2 | $1.31M | Sell |
56,016
-14,665
| -21% | -$314K | ﹤0.01% | 2428 |
|
|
2024
Q1 | $1.79M | Sell |
70,681
-175,593
| -71% | -$4.22M | ﹤0.01% | 2670 |
|
|
2023
Q4 | $5.75M | Buy |
246,274
+114,828
| +87% | +$2.26M | ﹤0.01% | 1969 |
|
|
2023
Q3 | $6.65M | Sell |
131,446
-11,632
| -8% | -$542K | ﹤0.01% | 1163 |
|
|
2023
Q2 | $6.68M | Buy |
143,078
+65,854
| +85% | +$3.02M | ﹤0.01% | 1181 |
|
|
2023
Q1 | $2.95M | Sell |
77,224
-26,328
| -25% | -$1.17M | ﹤0.01% | 1914 |
|
|
2022
Q4 | $5.67M | Buy |
103,552
+102,364
| +8,616% | +$4.39M | ﹤0.01% | 1532 |
|
|
2022
Q3 | $40K | Sell |
1,188
-10,890
| -90% | -$167K | ﹤0.01% | 3845 |
|
|
2022
Q2 | $114K | Buy |
12,078
+4,468
| +59% | +$46.6K | ﹤0.01% | 3716 |
|
|
2022
Q1 | $107K | Sell |
7,610
-27,820
| -79% | -$487K | ﹤0.01% | 3746 |
|
|
2021
Q4 | $749K | Buy |
35,430
+21,362
| +152% | +$474K | ﹤0.01% | 2998 |
|
|
2021
Q3 | $315K | Buy |
14,068
+8,592
| +157% | +$194K | ﹤0.01% | 3402 |
|
|
2021
Q2 | $136K | Sell |
5,476
-7,281
| -57% | -$205K | ﹤0.01% | 3721 |
|
|
2021
Q1 | $369K | Buy |
12,757
+6,819
| +115% | +$206K | ﹤0.01% | 3371 |
|
|
2020
Q4 | $153K | Sell |
5,938
-2,231
| -27% | -$62.1K | ﹤0.01% | 3918 |
|
|
2020
Q3 | $252K | Sell |
8,169
-9,230
| -53% | -$323K | ﹤0.01% | 3690 |
|
|
2020
Q2 | $434K | Buy |
17,399
+14,617
| +525% | +$334K | ﹤0.01% | 3447 |
|
|
2020
Q1 | $59K | Sell |
2,782
-2,236
| -45% | -$48K | ﹤0.01% | 5119 |
|
|
2019
Q4 | $112K | Buy |
5,018
+2,361
| +89% | +$48.8K | ﹤0.01% | 5417 |
|
|
2019
Q3 | $61K | Buy |
+2,657
| New | +$61.8K | ﹤0.01% | 5797 |
|
Other funds holding AKRO
Barclays's AKRO Position: Q4 2025 in Review
Barclays sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 487,230 shares — an estimated $23.1M sold.
Barclays first reported a position in AKRO in Q3 2019 and held it in 25 quarters. The position peaked at $28.5M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Barclays reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Barclays sold 487,230 Akero Therapeutics shares in Q4 2025, an estimated $23.1M.
- Barclays first reported a position in Akero Therapeutics in Q3 2019 and held it in 25 quarters.
- Barclays's Akero Therapeutics position peaked at $28.5M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.